

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Iptacopan for treating complement 3 glomerulopathy [ID6283]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

At the scoping consultation, the following equality issues were raised:

- Children (under 12 years of age) are excluded from the licence. Furthermore, the company indicated that its submission will exclude young people (under 18 years of age). Consultees noted that access for people of all ages should be considered.
- There is a longer waiting time for kidney transplants for black people and people with an Asian family background compared to white people. A third of people (35 per cent) waiting for a kidney across the UK are from minority ethnic groups but in 2017/18, of those providing their ethnicity when registering on the NHS Organ Donor Register, only 3.3 per cent had an Asian family background, 1 per cent were black and 2 per cent were mixed race.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee should consider iptacopan within its marketing authorisation (adult population), however the committee may consider whether [Commissioning Medicines for Children in Specialised Services](#) applies in this instance.

The committee should consider whether the longer waiting times faced by black people and people of Asian family backgrounds represents a health inequality, and if so the impact of guidance on this inequality.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No.

Approved by Associate Director (name):Lorna Dunning

Date: 7/1/25